[
  {
    "ts": "2026-02-28T07:21:55+00:00",
    "headline": "Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)",
    "summary": "CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $33 from $32 and maintained an Underweight rating on the shares. The firm stated that it refreshed its estimates on the stock […]",
    "url": "https://finance.yahoo.com/news/analysts-saying-crispr-therapeutics-ag-072155477.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "b3a432f2-b494-3238-bb8d-517294d25ae0",
      "content": {
        "id": "b3a432f2-b494-3238-bb8d-517294d25ae0",
        "contentType": "STORY",
        "title": "Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)",
        "description": "",
        "summary": "CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $33 from $32 and maintained an Underweight rating on the shares. The firm stated that it refreshed its estimates on the stock […]",
        "pubDate": "2026-02-28T07:21:55Z",
        "displayTime": "2026-02-28T07:21:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9emoTAGM5k9_AAOAzY4N1w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yzCQgik8395vyxH4EhUh.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-crispr-therapeutics-ag-072155477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-crispr-therapeutics-ag-072155477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T07:21:47+00:00",
    "headline": "Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results […]",
    "url": "https://finance.yahoo.com/news/analysts-saying-vertex-pharmaceuticals-vrtx-072147623.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "07e59b45-6ca3-3a20-939e-de3830aef9b1",
      "content": {
        "id": "07e59b45-6ca3-3a20-939e-de3830aef9b1",
        "contentType": "STORY",
        "title": "Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results […]",
        "pubDate": "2026-02-28T07:21:47Z",
        "displayTime": "2026-02-28T07:21:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l0DSaAhjgYrGYMIp84u.Dg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MOpM93.qarjxsgAhhmtxCQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-vertex-pharmaceuticals-vrtx-072147623.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-vertex-pharmaceuticals-vrtx-072147623.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]